BOCIC(SH:601696) Xin Lang Cai Jing·2025-09-23 06:32Group 1 - The core viewpoint of the news is that Sinovac Biotech experienced a decline in stock price, with a drop of 5.03% to 38.50 CNY per share, and a total market capitalization of 7.748 billion CNY [1] - Sinovac Biotech, established on August 22, 1997, specializes in the research, production, and sales of recombinant protein drugs and microbiological preparations, with 97.38% of its revenue coming from pharmaceutical products [1] - The trading volume for Sinovac Biotech was 133 million CNY, with a turnover rate of 1.68% [1] Group 2 - According to data, a fund under Bank of China Securities holds a significant position in Sinovac Biotech, with 182,300 shares, representing 4.41% of the fund's net value, making it the ninth-largest holding [2] - The Bank of China Securities Health Industry Mixed Fund (002938) has a total scale of 158 million CNY and has achieved a year-to-date return of 58.86%, ranking 653 out of 8172 in its category [2] - The fund manager, Li Mingwei, has been in position for 2 years and 215 days, with the best and worst fund returns during his tenure both at 4.82% [3]